Revive Therapeutics Ltd. · CSE:RVV
Revive Therapeutics — Investor Presentation (November 2023)
16 slides from Revive Therapeutics's investor presentation, November 2023
Slide 1: A Specialty Life Sciences Company
A SPECIALTY LIFE SCIENCES COMPANY Corporate Presentation November 2023 OTCQB: FRANKFURT: RVVTF 31R Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: [email protected]
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future f
Slide 3: Revive Therapeutics
REVIVE THERAPEUTICS Bucillamine Focused on the development Advancing novel use of Developing Psilocybin (oral and of therapeutics and Bucillamine for COVID and patch) for mental health diagnostics for infectious companion long COVID conditions and substance Psilocybin diseases, mental health and dia
Slide 4: Strategy
STRATEGY Clinical development of Targeting Infectious Novel Uses, Targeting FDA Bucillamine, Psilocybin, Diseases, Formulations, and Designations: and Long COVID Mental Health and Rare Delivery System Orphan, Fast track, diagnostics Disorders Breakthrough Therapy © COPYRIGHT 2020. Revive Therapeutic
Slide 5: Intellectual Property Portfolio
INTELLECTUAL PROPERTY PORTFOLIO Title USPTO No. Status Use of Bucillamine in the Treatment of Infectious Diseases, including COVID-19 62/991,996 Non-Provisional patent filed Use of Bucillamine in the Treatment of Gout US9662305 Granted - May 30, 2017 Use of Bucillamine in the Treatment of Neurologic
Slide 6: Product Pipeline
PRODUCT PIPELINE Focus on Infectious Diseases, Rare Disorders, Mental Illness Product Indication Stage of Development Regulatory Status Bucillamine Infectious Diseases Determining next steps Completed Phase 3 (Oral Tablet) COVID-19 and international opps Rare Inflammatory Bucillamine Disorders Phase
Slide 7: Infectious Disease Opportunity
INFECTIOUS DISEASE OPPORTUNITY Bucillamine potential for COVID- Bucillamine Revive’s clinical history Bucillamine scientific rationale as 19 Safety Profile with Bucillamine an intervention for COVID-19 (see Appendix) • Potential treatment for reduction in • Well-known safety profile and prescribed •
Slide 8: Long COVID Opportunity
LONG COVID OPPORTUNITY © COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. 8
Slide 9: Psychedelics Opportunity
PSYCHEDELICS OPPORTUNITY Psilocybin and MDMA Microneedle Patch Programs • Collaboration with PharmaTher (OTCQB: PHRRF, CSE: PHRM) for patch IP/Supply • Collaboration with PharmAla (CSE: MDMA) for MDMA supply Psilocybin for Substance Abuse Disorders Program • Collaboration with University of Wisconsi
Slide 10: Formulation & Delivery Technology
FORMULATION & DELIVERY TECHNOLOGY Delivering naturally extracted and synthetic psychedelics DELIVERY SYSTEM Combines Tannin (antibacterial, antifungal, antioxidant, wound healing) and Chitosan (blood-clotting and antimicrobial) composites Releases (rapid, controlled, sustained), improved bioavailabi
Slide 11: Strategic Partners
STRATEGIC PARTNERS Clinical Research Psilocybin Biosynthesis Long COVID Rapid Test Psilocybin Psilocybin and MDMA MDMA Supply Microneedle Patch © COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. 11
Slide 12: Expected Milestones
EXPECTED MILESTONES Q1 2024 • Complete reformulation of • Interim-results of Phase 1/2 study Bucillamine IV for future studies for Psilocybin (Methamphetamine in infectious diseases and Use Disorder) at University of ischemia-reperfusion Wisconsin • FDA meeting for LONG COVID • FDA pre-IND meeting f
Slide 13: Team
TEAM Management Clinical & Regulatory Board of Directors • Michael Frank • Dr. Kelly McKee, Jr., MD, MPH • Michael Frank Chairman and CEO Chief Scientific Officer, Consultant Chairman and CEO • Carmelo Marrelli • Dr. Arshi Kizilbash, M.D. • William Jackson Chief Financial Officer Medical Advisor, Co
Slide 14: Stock Information
STOCK INFORMATION Ticker 52-Week High/Low Market Cap R V V (CSE) | R V V T F (OTCQB) | 31R (Frankfurt) CAD $0.275 / $0.02 CAD ~ $10,500,000 Share Price Capital Structure CAD $0.03 (Nov 3, 2023) 357,646,841 common shares © COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. 14
Slide 15: Appendix – Bucillamine Scientific Rationale for COVID-19
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at-risk populations, such as the elderly.1,2 Novel antivirals have been plagued by poor oral bioavailability and lack of efficac
Slide 16: Appendix – Bucillamine Scientific Rationale for COVID-19 (References)
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 References 1. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
Revive Therapeutics — Investor Presentation (November 2023) on 6ix